The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Kerbauy
F R
FR
Tirapelli
B
B
Akabane
H
H
Oliveira
J S R
JS
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000175:diagnosis / Q000628:therapy*; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007938:Leukemia / Q000175:diagnosis / Q000628:therapy*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000628:therapy*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods*
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan